Last reviewed 2026-04-20 · How we verify

Aponeuron (AMFETAMINIL)

Phase 2 active Small molecule

Aponeuron (generic name: AMFETAMINIL) is a amfetaminil drug. It is currently in Phase 2 development for Narcolepsy.

Aponeuron works by increasing the levels of certain neurotransmitters in the brain, such as dopamine and norepinephrine, to enhance alertness and wakefulness.

Aponeuron, also known as amfetaminil, is a small molecule drug in the amfetaminil class. It is used to treat narcolepsy, a neurological disorder characterized by excessive daytime sleepiness. The commercial status of Aponeuron is currently unknown, and it is not clear if it is patented or available as a generic medication. Aponeuron's safety considerations are not well-documented, but it is likely to have similar side effects to other stimulant medications. Further research is needed to fully understand the pharmacology and safety of Aponeuron.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	AMFETAMINIL
Drug class	amfetaminil
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

Imagine your brain is a city, and the neurotransmitters are the messengers that help different parts of the city communicate. Aponeuron helps increase the number of these messengers, making it easier for the city to stay awake and alert. This is similar to how a stimulant like caffeine works, but Aponeuron is a more targeted and specific medication.

Approved indications

Narcolepsy

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Aponeuron CI brief — competitive landscape report
Aponeuron updates RSS · CI watch RSS

Frequently asked questions about Aponeuron

What is Aponeuron?

Aponeuron (AMFETAMINIL) is a amfetaminil drug, indicated for Narcolepsy.

How does Aponeuron work?

Aponeuron works by increasing the levels of certain neurotransmitters in the brain, such as dopamine and norepinephrine, to enhance alertness and wakefulness.

What is Aponeuron used for?

Aponeuron is indicated for Narcolepsy.

What is the generic name of Aponeuron?

AMFETAMINIL is the generic (nonproprietary) name of Aponeuron.

What drug class is Aponeuron in?

Aponeuron belongs to the amfetaminil class. See all amfetaminil drugs at /class/amfetaminil.

What development phase is Aponeuron in?

Aponeuron is in Phase 2.

Drug class: All amfetaminil drugs
Therapeutic area: All drugs in Neuroscience
Indication: Drugs for Narcolepsy

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing